Two Cases of Advanced Hepatocellular Carcinoma Who Responded Well to the Combination of Durvalumab Plus Tremelimumab After Disease Progression During Atezolizumab Plus Bevacizumab Therapy Under Bevacizumab Withdrawal

Many systemic chemotherapies, including immune checkpoint inhibitors (ICI), are now available for the treatment of advanced hepatocellular carcinoma. On the other hand, it is often difficult to continue administration of angiogenesis inhibitors in these patients due to various side effects. In the t...

Descripción completa

Detalles Bibliográficos
Autores principales: Kawamura, Yusuke, Akuta, Norio, Fujiyama, Shunichiro, Suzuki, Fumitaka, Kumada, Hiromitsu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Gastroenterology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10579722/
https://www.ncbi.nlm.nih.gov/pubmed/37854758
http://dx.doi.org/10.7759/cureus.45385

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10579722/
https://www.ncbi.nlm.nih.gov/pubmed/37854758
http://dx.doi.org/10.7759/cureus.45385

Ejemplares similares